NVLT:
Novelos Therapeutics, Inc., a biopharmaceutical company, commercializes oxidized glutathione-based compounds for the treatment of cancer and hepatitis in the United States. Its products in development include NOV-002, which acts as a chemoprotectant and an immunomodulator; and NOV-205, which acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-002, a small-molecule formulation of a natural metabolite, is in Phase III development for lung cancer, as well as in Phase II development for chemotherapy-resistant ovarian cancer and early-stage breast cancer. NOV-002 is also being developed for acute radiation injury. NOV-205, a small-molecule formulation of oxidized glutathione and inosine, is in Phase Ib development for the treatment of chronic hepatitis C. Novelos Therapeutics is based in Newton, Massachusetts.
I need to do some research on the compounds--eg how they work etc, and will post. Very interesting mechanisms of action.
Subscribe to:
Post Comments (Atom)
1 comment:
Did you ever look into this? An article was just published about Nov-002, one of their drugs in "Expert Opinion on Investigational Drugs" - interested in your opinion on it.
Post a Comment